Smart Weapons Prove Tough to Design
- 18 October 2002
- journal article
- other
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 298 (5593) , 522-525
- https://doi.org/10.1126/science.298.5593.522
Abstract
Data from several clinical trials of Iressa, an experimental drug in a new class of targeted cancer therapies, have been inconsistent, and some have been flatly disappointing. Even so, on 24 September, the U.S. Food and Drug Administration's Oncology Drug Advisory Committee voted 11 to 3 to recommend that the agency approve the drug to treat a common form of lung cancer, known as non-small-cell lung cancer. The agency now has less than 6 months to decide whether to allow Iressa on the market, and the lobbying has been intense.Keywords
This publication has 0 references indexed in Scilit: